This is a blend. GLP-3 RT and Cagri are combined in a single vial: 12.5 mg of GLP-3 RT and 2.5 mg of Cagri. Both appear in metabolic research, but they act on different receptor systems. GLP-3 RT is a triple agonist at the GLP-1, GIP and glucagon receptors. Cagri is a long-acting amylin analogue that acts on amylin and calcitonin receptors. Researchers use blends to compare combined conditions against single compounds.
The numbers that define GLP-3 / Cagri and how it is being studied. For laboratory research use only.
5
Receptor Targets
GLP-1R · GIPR · GCGR · amylin · calcitonin
12.5 / 2.5
mg Per Vial
GLP-3 RT / Cagri
~6-7 d
Component Half-Lives
Both lipidated for albumin binding
4
Research Areas
Multi-Receptor Metabolic Research
Amylin + Incretin Combinations
Glycemic Pathways
How It Works
How GLP-3 / Cagri works
The pathways GLP-3 / Cagri acts on - and what each one does. The animation traces its signal outward from the compound to every target it engages.
Signalling pathways studied in preclinical models · illustrative
Triple Incretin & Glucagon Agonism
GLP-3 RT
GLP-3 RT binds GLP-1, GIP and glucagon receptors. Published characterisation describes glucose-dependent insulin secretion, appetite-pathway signalling and hepatic energy expenditure in study models.
GLP-1 receptor agonism
GIP receptor co-agonism
Glucagon receptor agonism
Amylin & Calcitonin Receptor Agonism
Cagri
Cagri is a long-acting amylin analogue. It activates amylin receptors and the calcitonin receptor, with satiety signalling, gastric emptying and post-meal glucagon as measured endpoints.
Amylin receptor agonism
Calcitonin receptor co-activation
Hindbrain satiety signalling
Complementary Receptor Systems
Synergy
The two components act through non-overlapping receptor families: incretin and glucagon receptors for GLP-3 RT, amylin and calcitonin receptors for Cagri. Amylin analogues are studied alongside incretin agonists in combination research.
Non-overlapping receptor families
Incretin + amylin pathway coverage
Studied as a combined condition
Uses & Applications
What GLP-3 / Cagri is researched for
The main areas GLP-3 / Cagri is being studied for - and the study-reported figures behind them.
Metabolic
Multi-Receptor Metabolic Research
GLP-3 RT covers three incretin and glucagon receptors; Cagri adds the amylin system. The blend is studied as a five-receptor combined condition.
Combination
Amylin + Incretin Research
Amylin analogues are studied alongside GLP-1-pathway agonists because the two act through different receptors and neural pathways.
Endocrine
Glycemic Pathway Research
Both components are studied for glycemic endpoints: glucose-dependent insulin secretion for GLP-3 RT, post-meal glucagon and gastric emptying for Cagri.
Neuroscience
Satiety Circuitry
Hypothalamic GLP-1 signalling and hindbrain amylin signalling are both studied for their roles in satiety pathways.
Study-reported magnitudes
Representative figures from published research. Bars fill as you scroll.
HPLC Purity (lot COA)≥99%
Sterility & Endotoxin ScreenPASSED
Net Content & IdentityPASSED
Figures are representative of published research findings and shown for reference.
Molecular Structure
The GLP-3 / Cagri molecule
An interactive 3D model rendered from the compound record - rotate and explore its structure.
Each vial contains 12.5 mg of GLP-3 RT and 2.5 mg of Cagri, lyophilized together. GLP-3 RT is a triple GLP-1/GIP/glucagon receptor agonist; Cagri is a long-acting amylin analogue.
The two act on different receptor systems. GLP-3 RT targets incretin and glucagon receptors, while Cagri targets amylin and calcitonin receptors. The combination covers both pathway families in one condition.
No. The combination has not been characterised as a single formulation. The rationale is based on mechanisms described for each component individually.
No. This blend is sold exclusively for in vitro laboratory research purposes and is not intended for human or animal consumption, diagnosis, or treatment.
Store lyophilized at -20°C for long-term stability, protected from light and moisture, and avoid repeated freeze-thaw cycles.
Research Use Only.
Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.
